|
TSX.V: IXS,
OTCBB: IXSBF
VANCOUVER, Nov. 18 /PRNewswire-FirstCall/ - InNexus Biotechnology, Inc.
is pleased to announce the appointment of Dr. Heinz Kohler to Vice-President
of Research. He will assume this role immediately and is the original inventor
of SuperAntibody(TM) Technology. Dr. Kohler has been the Companys Acting Head
of Research and Development.
Dr. Kohler was instrumental in the start-up phase of one of the most
successful biotech companies, IDEC Pharmaceuticals, as the Director of
Research and holds both an MD and Ph.D. degree. He is world renowned in the
development of monoclonal antibodies and has authored and contributed to over
200 peer-reviewed publications and is listed as Inventor on numerous
inventions and patents.
Dr. Kohler has previously held the roles of Professor at the University
of Chicago, the University of SUNY at Buffalo, the University of California
San Diego and Director of Molecular Immunology at the Roswell Park Cancer
Center. He also helped to found Immpheron Inc. of Lexington, Kentucky, which
currently manages InNexus Coldstream Research Laboratory.
About InNexus
InNexus is an innovative antibody-driven drug development company that
has developed two technology platforms, SuperAntibody(TM) and TransMAbs(TM),
which improve the potency of existing antibody products while opening new
markets and disease applications. Both platforms utilize unique, novel and
patented methods and technologies of InNexus. InNexus is headquartered in
British Columbia, Canada and has its own in-house developmental facilities.
These development facilities provide validation of protein and peptide
discoveries, enabling InNexus (and its strategic partners) to advance novel
drug therapeutics and diagnostics. To learn more about InNexus please visit
http://www.innexusbiotech.com.
This news release contains forward-looking statements within the meaning
of the Private Securities Litigation Reform Act of 1995. These statements are
not historical facts and are subject to risks and uncertainties which could
cause actual results and the timing of certain events to differ materially
from those set forth in or implied herein including, without limitation, risks
associated with clinical development, regulatory approvals, product
commercialization, intellectual property claims litigation and other risks
associated with the Companys proposed activities.
On behalf of the Board of Directors of InNexus Biotechnology, Inc.
Dr. A. Charles Morgan
President
To contact us:
Telephone: (877) 990-8382
Fax: (425) 696-0068
Email: business@innexusbiotech.com
Investor Relations:
Telephone: (866) 990-8382
Email: investor@innexusbiotech.com
The TSX Venture Exchange has neither approved nor disapproved of the
information contained herein.
|
|
